A Phase 2 interventional study of enzastaurin and pemetrexed in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-13.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 33 under way, 12 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 49th largest by enrollment of the 224 interventional ones that give a count, is one of 25 that started in 2006, is one of 128 in phase 2, and was the 32nd registered.
7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
228 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 48 · Phase 4 8
First in 2001; this study’s year is marked. 25 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 218 is above the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 65 across the 224 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 228 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 37th largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2006, is one of 73 in phase 2, and was the 36th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purposes of this study are to determine:
The safety of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin, or docetaxel with carboplatin and any side effects that might be associated with the combination of these drugs.
Whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can help participants with non-small cell lung cancer (NSCLC) live longer, compared with the combination of docetaxel and carboplatin.
Whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can make your tumor smaller or disappear, and for how long, compared with the combination of docetaxel and carboplatin.
The effects of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin or docetaxel with carboplatin have on your disease related symptoms.
The relation of smoking history and hormone replacement therapy (for women only) may have to your lung cancer treatment results.
The effects of certain genes and proteins in samples of your blood and tumor tissue in order to learn more about NSCLC and how enzastaurin works in the body.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: enzastaurin · Drug: pemetrexed · Drug: carboplatin
Drug: pemetrexed · Drug: carboplatin
Drug: docetaxel · Drug: carboplatin
1125-1200 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
Also known as: LY317615
500 milligrams per square meter (mg/m\^2), intravenous (IV), once every (q) 21 days, six 21 day cycles or progressive disease
Also known as: LY231514, Alimta
75 mg/m\^2, IV, q 21 days, six 21 day cycles or progressive disease
Area under the curve (AUC) 6, IV, q 21 days, six 21 day cycles or progressive disease
Time to Disease Progression
Time to disease progression was defined as the time from randomization to the first date of documented disease progression or death if the participant dies due to disease progression. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Progressive disease (PD) was defined as having at least a 20% increase in sum of the longest diameter of target lesions. For participants who have not had documented disease progression, time to disease progression was censored at the date of death or date of last visit. For participants who received other anti-tumor therapy prior to disease progression, time to disease progression was censored at the first available date of other anti-tumor therapy.
Time frame: Baseline to measured PD up to 22.3 months
Tumor Biomarkers Associated With Clinical Outcomes
As specified in the protocol, tumor biomarker samples were collected from participants on the pemetrexed arms only but were not intended to be analyzed at the individual study level.
Time frame: Baseline, Cycle 1, Cycle 2 (21-day cycle each), and 30-day post study treatment follow-up
Assessment of Smoking History (All Participants) and Hormone Replacement Therapy (Female Participants Only) Associated With Clinical Outcomes
Data for smoking history and hormone replacement therapy were collected but were not intended to be analyzed at the individual study level.
Time frame: Baseline
Number of Participants With Adverse Events (AEs) or Deaths
Data presented are the number of participants who experienced 1 or more AEs or any serious AEs (SAEs) regardless of causality, or deaths during the study including 30 days after treatment discontinuation. A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events section of this report.
Time frame: Baseline through study completion up to 6 cycles (21-day cycle each) and 30-day safety follow-up
Change From Baseline in Total Functional Assessment of Cancer Therapy-Lung (FACT-L) Scale
The FACT-L version 4 scale is used to assess health-related quality of life (HRQoL) in participants with lung cancer. The FACT-L has 5 subscales: Physical Well-Being (PWB), Social and Family Well-Being (SFWB) and Functional Well-Being (FWB) subscales which include 7 items each, Emotional Well-Being (EWB) subscale which includes 6 items, and a Lung-Cancer Specific (LCS) subscale which include 7 items. Total FACT-L is the sum of all 5 subscales. Each item is scored from 0 to 4 giving a total overall score from 0 equal to "worst quality of life" to 136 equal to "best quality of life". The Least Square (LS) mean was calculated using an analysis of covariance (ANCOVA) model adjusted for change scores and baseline scores.
Time frame: Baseline, Cycle 1 (Week 3), Cycle 2 (Week 6), Cycle 3 (Week 9), Cycle 4 (Week 12), Cycle 5 (Week 15) and Cycle 6 (Week 18) [21-day cycle each]
Change From Baseline in Total Functional Assessment of Cancer Therapy -Taxane (FACT-Taxane) Scale
The FACT-Taxane version 4 scale is used to assess HRQoL in participants receiving taxane chemotherapy. The FACT-taxane has 5 subscales: PWB, SFWB, and FWB subscales which include 7 items each, EWB subscale which includes 6 items, and a taxane subscale which include 16 items and has two domains (neurotoxicity and taxane). Total FACT-Taxane is the sum of all the 5 subscales. Each item is scored from 0 to 4 giving a total overall score from 0 "worst quality of life" to 172 "best quality of life". The LS mean was calculated using an ANCOVA model adjusted for change scores and baseline scores.
Time frame: Baseline, Cycle 1 (Week 3), Cycle 2 (Week 6), Cycle 3 (Week 9), Cycle 4 (Week 12), Cycle 5 (Week 15) and Cycle 6 (Week 18) [21-day cycle each]
Overall Survival (OS)
OS was the duration from the date of randomization to the date of death from any cause. For participants who were alive, OS was censored at the date of last follow-up visit or at the date of last contact.
Time frame: Baseline to date of death from any cause up to 35 months
Number of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response]
Response was defined using RECIST, version 1.0 criteria. Participants with a best response of CR or PR were considered to have had a tumor response. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.
Time frame: Baseline to measured PD up to 22.3 months
Duration of CR or PR (Duration of Response)
The duration of a CR or PR was defined as the time from first objective status assessment of CR or PR to the first time of progression or death due to any cause. Response was defined using RECIST, version 1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.
Time frame: Date of first response to the date of progression or death due to any cause up to 22.3 months
Time-to-Treatment Failure (TTF)
TTF was defined as the time from randomization to the first observation of PD, death due to any cause, or early discontinuation of treatment. Response was defined using RECIST, version 1.0 criteria. PD was defined as having at least a 20% increase in sum of longest diameter of target lesions. TTF was censored at the date of the last follow-up visit for participants who did not discontinue early, who were still alive, and who have not progressed.
Time frame: Baseline to stopping treatment up to 14.1 months
| Milestone | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin |
|---|---|---|---|
| Started | 72 | 74 | 72 |
| Received at least 1 dose of study drug | 67 | 72 | 70 |
| Completed | 0 | 34 | 23 |
| Not completed | 72 | 40 | 49 |
| Withdrew: Adverse event | 9 | 9 | 13 |
| Withdrew: Withdrawal by subject | 6 | 2 | 3 |
| Withdrew: Physician decision | 3 | 4 | 3 |
| Withdrew: Sponsor decision | 1 | 0 | 0 |
| Withdrew: Disease progression | 47 | 24 | 28 |
| Withdrew: Unrelated complication | 3 | 0 | 1 |
| Withdrew: Death | 1 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: New primary disease identified | 1 | 1 | 0 |
Time to disease progression was defined as the time from randomization to the first date of documented disease progression or death if the participant dies due to disease progression. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Progressive disease (PD) was defined as having at least a 20% increase in sum of the longest diameter of target lesions. For participants who have not had documented disease progression, time to disease progression was censored at the date of death or date of last visit. For participants who received other anti-tumor therapy prior to disease progression, time to disease progression was censored at the first available date of other anti-tumor therapy.
| months | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin |
|---|---|---|---|
| Time to Disease Progression | 4.6 (3.2 to 6.7) | 6.0 (4.6 to 6.5) | 4.1 (2.6 to 6.3) |
As specified in the protocol, tumor biomarker samples were collected from participants on the pemetrexed arms only but were not intended to be analyzed at the individual study level.
No measurements were reported for this outcome.
Data for smoking history and hormone replacement therapy were collected but were not intended to be analyzed at the individual study level.
No measurements were reported for this outcome.
Data presented are the number of participants who experienced 1 or more AEs or any serious AEs (SAEs) regardless of causality, or deaths during the study including 30 days after treatment discontinuation. A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events section of this report.
| Participants | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin |
|---|---|---|---|
| AEs | 63 | 70 | 69 |
| SAEs | 35 | 20 | 26 |
| Deaths Due to AEs | 3 | 5 | 4 |
The FACT-L version 4 scale is used to assess health-related quality of life (HRQoL) in participants with lung cancer. The FACT-L has 5 subscales: Physical Well-Being (PWB), Social and Family Well-Being (SFWB) and Functional Well-Being (FWB) subscales which include 7 items each, Emotional Well-Being (EWB) subscale which includes 6 items, and a Lung-Cancer Specific (LCS) subscale which include 7 items. Total FACT-L is the sum of all 5 subscales. Each item is scored from 0 to 4 giving a total overall score from 0 equal to "worst quality of life" to 136 equal to "best quality of life". The Least Square (LS) mean was calculated using an analysis of covariance (ANCOVA) model adjusted for change scores and baseline scores.
| units on a scale | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin |
|---|---|---|---|
| Cycle 1 (Week 3) | -3.98 ± 1.86 | 1.12 ± 1.78 | -3.33 ± 1.88 |
| Cycle 2 (Week 6) | -3.25 ± 2.19 | -1.54 ± 2.08 | -2.16 ± 2.42 |
| Cycle 3 (Week 9) | 0.39 ± 2.30 | 0.64 ± 2.25 | -1.93 ± 2.49 |
| Cycle 4 (Week 12) | 0.31 ± 2.47 | 3.54 ± 2.23 | -0.81 ± 2.50 |
| Cycle 5 (Week 15) | 1.89 ± 2.95 | -0.26 ± 2.57 | -4.69 ± 2.79 |
| Cycle 6 (Week 18) | 7.38 ± 3.54 | -0.83 ± 2.84 | 3.38 ± 3.54 |
The FACT-Taxane version 4 scale is used to assess HRQoL in participants receiving taxane chemotherapy. The FACT-taxane has 5 subscales: PWB, SFWB, and FWB subscales which include 7 items each, EWB subscale which includes 6 items, and a taxane subscale which include 16 items and has two domains (neurotoxicity and taxane). Total FACT-Taxane is the sum of all the 5 subscales. Each item is scored from 0 to 4 giving a total overall score from 0 "worst quality of life" to 172 "best quality of life". The LS mean was calculated using an ANCOVA model adjusted for change scores and baseline scores.
| units on a scale | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin |
|---|---|---|---|
| Cycle 1 (Week 3) | -3.16 ± 2.20 | -0.78 ± 2.08 | -2.17 ± 2.20 |
| Cycle 2 (Week 6) | -6.22 ± 2.90 | -5.66 ± 2.76 | -3.13 ± 3.16 |
| Cycle 3 (Week 9) | -1.89 ± 3.35 | -1.52 ± 3.32 | -4.40 ± 3.62 |
| Cycle 4 (Week 12) | -2.28 ± 3.65 | -0.77 ± 3.29 | -2.58 ± 3.74 |
| Cycle 5 (Week 15) | -2.52 ± 3.71 | -3.11 ± 3.24 | -7.74 ± 3.51 |
| Cycle 6 (Week 18) | 2.77 ± 3.93 | -2.81 ± 3.26 | -0.34 ± 4.06 |
OS was the duration from the date of randomization to the date of death from any cause. For participants who were alive, OS was censored at the date of last follow-up visit or at the date of last contact.
| months | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin |
|---|---|---|---|
| Overall Survival (OS) | 7.2 (5.7 to 11.2) | 12.7 (9.3 to 17.0) | 9.2 (5.9 to 10.7) |
Response was defined using RECIST, version 1.0 criteria. Participants with a best response of CR or PR were considered to have had a tumor response. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.
| Participants | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin |
|---|---|---|---|
| Number of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response] | 9 | 16 | 19 |
The duration of a CR or PR was defined as the time from first objective status assessment of CR or PR to the first time of progression or death due to any cause. Response was defined using RECIST, version 1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.
| months | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin |
|---|---|---|---|
| Duration of CR or PR (Duration of Response) | 7.4 (3.7 to 8.8) | 9.3 (5.7 to 14.8) | 5.8 (3.3 to 11.3) |
TTF was defined as the time from randomization to the first observation of PD, death due to any cause, or early discontinuation of treatment. Response was defined using RECIST, version 1.0 criteria. PD was defined as having at least a 20% increase in sum of longest diameter of target lesions. TTF was censored at the date of the last follow-up visit for participants who did not discontinue early, who were still alive, and who have not progressed.
| months | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin |
|---|---|---|---|
| Time-to-Treatment Failure (TTF) | 2.6 (1.7 to 3.7) | 3.8 (2.8 to 5.1) | 2.6 (1.3 to 3.7) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enzastaurin/Pemetrexed/Carboplatin | — | 35/67 (52.2%) | 63/67 (94%) |
| Pemetrexed/Carboplatin | — | 20/72 (27.8%) | 70/72 (97.2%) |
| Docetaxel/Carboplatin | — | 26/70 (37.1%) | 69/70 (98.6%) |
| Event | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin |
|---|---|---|---|
| PneumoniaInfections and infestations | 7/67 | 3/72 | 2/70 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/67 | 1/72 | 6/70 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 5/67 | 0/72 | 3/70 |
| DehydrationMetabolism and nutrition disorders | 4/67 | 1/72 | 5/70 |
| HaemoglobinInvestigations | 4/67 | 3/72 | 2/70 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/67 | 2/72 | 2/70 |
| SepsisInfections and infestations | 2/67 | 0/72 | 4/70 |
| ArrhythmiaCardiac disorders | 3/67 | 1/72 | 1/70 |
| Chest painGeneral disorders | 3/67 | 0/72 | 0/70 |
| Blood potassium decreasedInvestigations | 3/67 | 0/72 | 0/70 |
| Event | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin |
|---|---|---|---|
| HaemoglobinInvestigations | 40/67 | 53/72 | 34/70 |
| Neutrophil countInvestigations | 33/67 | 37/72 | 46/70 |
| Platelet countInvestigations | 37/67 | 43/72 | 18/70 |
| FatigueGeneral disorders | 28/67 | 39/72 | 35/70 |
| NauseaGastrointestinal disorders | 34/67 | 32/72 | 24/70 |
| White blood cell countInvestigations | 23/67 | 29/72 | 21/70 |
| ConstipationGastrointestinal disorders | 17/67 | 25/72 | 17/70 |
| AlopeciaSkin and subcutaneous tissue disorders | 4/67 | 6/72 | 20/70 |
| DiarrhoeaGastrointestinal disorders | 18/67 | 10/72 | 19/70 |
| Decreased appetiteMetabolism and nutrition disorders | 12/67 | 12/72 | 19/70 |
All randomized participants.
| Age, Continuous(years) | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin | Total |
|---|---|---|---|---|
| Mean | 65.2 ± 9.8 | 64.0 ± 10.0 | 64.0 ± 9.1 | 64.4 ± 9.8 |
| Sex: Female, Male(Participants) | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin | Total |
|---|---|---|---|---|
| Female | 31 | 33 | 30 | 94 |
| Male | 41 | 41 | 42 | 124 |
| Race/Ethnicity, Customized(Participants) | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin | Total |
|---|---|---|---|---|
| African | 5 | 11 | 8 | 24 |
| Caucasian | 62 | 63 | 63 | 188 |
| Hispanic | 5 | 0 | 1 | 6 |
| Region of Enrollment(Participants) | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin | Total |
|---|---|---|---|---|
| United States | 72 | 74 | 72 | 218 |
| Disease Stage at Study Entry(Participants) | Enzastaurin/Pemetrexed/Carboplatin | Pemetrexed/Carboplatin | Docetaxel/Carboplatin | Total |
|---|---|---|---|---|
| Stage IIIB | 6 | 5 | 6 | 17 |
| Stage IV | 66 | 69 | 66 | 201 |
The record gives a start of Mar 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2021, 11 years 10 months after primary completion. A results delay was requested in May 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Enzastaurin · Pemetrexed
Carcinoma, Non-Small-Cell Lung →